valsartan has been researched along with Chronic Disease in 95 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.05) | 18.2507 |
| 2000's | 26 (27.37) | 29.6817 |
| 2010's | 54 (56.84) | 24.3611 |
| 2020's | 14 (14.74) | 2.80 |
| Authors | Studies |
|---|---|
| Calò, L; Cicogna, F; De Ruvo, E; Gaudio, C; Mennuni, S; Monzo, L; Petronilli, V; Tota, C | 1 |
| Bedhomme, S; Bouchant, S; Boussageon, R; Bœuf-Gibot, S; Charuel, E; Menini, T; Pereira, B; Piñol-Domenech, N; Vaillant-Roussel, H | 1 |
| Bian, Q; Guan, Y; Liu, H; Liu, Y | 1 |
| Tsutsui, H | 1 |
| Hellenkamp, K; Valentova, M; von Haehling, S | 1 |
| Li, Y; Liu, Z; Wang, J | 1 |
| Gao, Y; Hao, W; Hou, A; Luan, B; Wang, L; Xing, C; Zhao, H | 1 |
| Buckley, LF; Shah, AM | 1 |
| Chen, X; Du, F; Gao, Z; Hua, H; Jing, X; Li, S; Sun, G; Sun, J; Xiao, Y; Xu, W | 1 |
| Ängerud, KH; Bergdahl, E; Lindmark, K; Norberg, H | 1 |
| Danzi, GB; De Maria, R; Di Tano, G; Loffi, M; Verde, S | 1 |
| Haynes, R; Judge, PK | 1 |
| Bapat, D; Butler, J; Camacho, A; Felker, GM; Ibrahim, NE; Januzzi, JL; Maisel, A; Piña, IL; Solomon, SD; Ward, JH; Williamson, KM | 1 |
| Camerotto, A; Cuppini, S; Mazza, A; Minuz, P; Rigatelli, G; Rubello, D; Schiavon, L; Torin, G; Townsend, DM | 1 |
| Brunetti, ND; Correale, M; Di Biase, M; Diella, C; Ferraretti, A; Iacoviello, M; Mallardi, A; Mazzeo, P; Merolla, G; Romano, V; Tricarico, L | 1 |
| Bauersachs, J; Bavendiek, U; Kempf, T | 1 |
| Kherad, B; Krackhardt, F; Kresoja, KP; Schmidt, G; Spillmann, F; Tschöpe, C | 1 |
| Abadir, P; Ansari, A; Berger, A; Beselman, A; Budman, J; Faghih, M; Fedarko, N; Harmon, J; Hosseini, S; Inagami, T; Keenahan, K; Lay, F; Marti, G; Rini, D; Smith, B; Tian, J; Vuong, D; Walston, J | 1 |
| Ademi, Z; Deschaseaux, C; Hancock, E; Haroun, RH; Pfeil, AM; Schwenkglenks, M; Trueman, D | 1 |
| de Boer, RA; Koenders, JMA; Linssen, GCM; Meeder, JG; Ramos, IC; Rutten-van Mölken, MPMH; Versteegh, MM | 1 |
| Briggs, A; Cowie, MR; Deschaseaux, C; Hancock, E; Haroun, R; Lacey, M; McMurray, JJV; Mumby-Croft, J; Taylor, M; Trueman, D; Woodcock, F | 1 |
| Liu, RC | 1 |
| Arrigo, M; Beauvais, F; Cohen-Solal, A; Launay, JM; Logeart, D; Nougué, H; Pezel, T; Picard, F; Sadoune, M; Vodovar, N | 1 |
| Hong, GR; Kang, DH; Kim, JJ; Kim, MS; Lee, S; Park, SJ; Park, SW; Shin, SH; Song, JM; Yun, SC | 1 |
| Appadurai, V; Malpas, T; Nicolae, M; Thoreau, J | 1 |
| De Marco, A; Fragasso, G; Gemma, M; Margonato, A; Pinto, G; Silipigni, C; Spoladore, R; Tondi, L | 1 |
| Dalmaso, SG; Marchitto, N; Mobilia, P; Raimondi, G; Sindona, F | 1 |
| Bentivenga, C; Berardi, E; Borghi, C; Cosentino, ER; Degli Esposti, D; Dugato, V; Fg Cicero, A; Landolfo, M; Magri, G; Miceli, R; Spinardi, L | 1 |
| Mboumi, K; Severini, D | 1 |
| Hong, SH; Kim, H; Kim, S; Lee, EK; Park, SK | 1 |
| Bramlage, P; Ferrero, C; Gomez, T; Minguet, J; Sutton, G | 1 |
| Widimský, J | 1 |
| Lillyblad, MP | 1 |
| Traynor, K | 1 |
| Macdonald, PS | 1 |
| Bress, AP; King, JB; Munger, MA; Reese, AD | 1 |
| Nguyen, E; Weeda, ER; White, CM | 1 |
| Bělohlávek, J | 1 |
| Giannitsis, E; Huber, K; Jaffe, AS; Lindahl, B; Mair, J; Möckel, M; Müller, C; Plebani, M; Thygesen, K | 1 |
| McCormack, PL | 1 |
| Latini, R; Masson, S; Staszewsky, L | 1 |
| Bruhn, C | 1 |
| Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I | 1 |
| Fath, R | 1 |
| Greenberg, B; Hsiao, R | 1 |
| Parker, JD; Ross, HJ | 1 |
| Hein, L; Lother, A | 1 |
| Díez, J | 1 |
| Cook, JC; Patterson, JH; Rodgers, JE; Tran, RH | 1 |
| Alfonso Manterola, F; Almenar Bonet, L; Ariza Solé, A; Arribas Ynsaurriaga, F; Bover Freire, R; Bueno, H; Coca Payeras, A; Díaz Molina, B; Evangelista Masip, A; Ferreira González, I; González Juanatey, JR; Jiménez Navarro, M; Lambert Rodríguez, JL; López de Sá, E; López Fernández, S; Manito Lorite, N; Marin Ortuño, F; Martín Asenjo, R; Mirabet Pérez, S; Pascual Figal, D; Pérez de Isla, L; Rodríguez Padial, L; Ruilope Urioste, LM; San Román Calvar, JA; Sánchez Fernández, PL; Segovia Cubero, J; Sionis Green, A; Sionis, A; Varela Román, A; Vázquez García, R; Zamorano Gómez, JL | 1 |
| Cheng, J | 1 |
| Guo, W; Ito, H; Momomura, S; Ohishi, T; Okino, N; Saito, Y; Tsutsui, H; Yamamoto, K | 1 |
| Teerlink, JR; Tyler, JM | 1 |
| Böhm, M; Gong, J; Jhund, PS; Lefkowitz, MP; McMurray, JJV; Packer, M; Rizkala, AR; Rouleau, JL; Shi, VC; Solomon, SD; Swedberg, K; Young, R; Zile, MR | 1 |
| Anand, IS; Bishu, K; Cohn, JN; Ishani, A; Kuskowski, MA; Rector, TS | 1 |
| Iannazzo, S; Pradelli, L; Zaniolo, O | 1 |
| Ekhlas, A; Esnault, VL; Moranne, O; Nguyen, JM | 1 |
| Suzuki, H; Takenaka, T | 1 |
| Battaglia, G; Cambareri, F; Carminati, S; Cravedi, P; David, S; Ene-Iordache, B; Gaspari, F; Granata, A; Ledda, F; Loriga, G; Motterlini, N; Perna, A; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Satta, A; Stucchi, N; Tonelli, M | 1 |
| Kamide, K; Maekawa, Y; Ohishi, M; Onishi, M; Rakugi, H; Takeya, Y; Tatara, Y; Yamamoto, K | 1 |
| Hosoya, T; Ishii, T; Kawamura, T; Tsuboi, N | 1 |
| Chaiyakunapruk, N; Cheewasithirungrueng, N; Dilokthornsakul, P; Jeanpeerapong, N; Nimpitakpong, P; Srisupha-olarn, W; Thanarungroj, A | 1 |
| Chae, DW; Do, JY; Huh, W; Jang, HR; Kim, DJ; Kim, SG; Kim, YG; Lee, JE; Lee, YJ; Oh, HY | 1 |
| Derbentseva, EA; Dralova, OV; Maksimov, MA; Ostroumova, OD; Starodubtsev, AK | 1 |
| Aparasu, RR; Ashton, CM; Chen, H; Desai, RJ; Deswal, A; Johnson, ML; Mehta, HB; Morgan, RO | 1 |
| Hemmelder, MH; Janssen, WM; Lambers Heerspink, HJ; Laverman, GD; Navis, G; Slagman, MC; Waanders, F; Woittiez, AJ | 1 |
| Chen, C; Le, X; Sun, S; Tang, Y; Wang, M; Yin, Y | 1 |
| Kumagai, H; Matsubara, H; Oda, T; Ohshima, N; Senda, M; Tadano, H; Takechi, H; Uchida, T; Watanabe, A; Yamamoto, K | 1 |
| Auleley, GR; Boutron, I; Konrat, C; Ravaud, P; Ricordeau, P; Trinquart, L | 1 |
| Anand, I; Bevilacqua, M; Cardano, P; Chiang, YT; Cohn, JN; Dunselman, PH; Holwerda, NJ; Judd, D; Latini, R; Maggioni, AP; Masson, S; Salio, M; Tognoni, G | 1 |
| Hollenberg, NK | 1 |
| Aros, C; Bertocchi, F; Campbell, R; Fagiani, L; Perna, A; Perticucci, E; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F; Viscarra, C | 1 |
| Kohno, M | 1 |
| Anand, IS; Chiang, YT; Cohn, JN; Glazer, R; Latini, R; Masson, S | 1 |
| McMurray, JJ; Swedberg, K | 1 |
| Suzuki, H | 1 |
| Anavekar, NS; Califf, RM; Dickstein, K; Kober, L; Leimberger, JD; Maggioni, A; McMurray, JJ; Nordlander, R; Pfeffer, MA; Rouleau, JL; Solomon, SD; Velazquez, EJ; White, HD; Zelenkofske, S | 1 |
| Aknay, N; Anand, IS; Chiang, YT; Cohn, JN; Florea, VG; Glazer, RD; Hester, A; Kuskowski, MA; Latini, R; Maggioni, AP; Opasich, C; Rector, TS | 1 |
| Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV | 1 |
| Barrios Alonso, V; Calderón Montero, A; Escobar Cervantes, C | 1 |
| Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV | 1 |
| Anand, I; Carretta, E; Cohn, J; Glazer, R; Ingrillì, F; Krum, H; Latini, R; Maggioni, AP; Masson, S; Pettinati, G; Tognoni, G | 1 |
| Cohn, JN | 1 |
| Akazawa, H; Komuro, I; Kudo, Y | 1 |
| Deswal, A; Mann, DL; Ramasubbu, K | 1 |
| Chen, WD; Huang, YY; Li, LH; Wang, YW; Xu, HH; Yang, LC; Yang, YL; Zhang, DY; Zhu, XJ | 1 |
| Cohn, JN; Glazer, RD; Hester, A; Spormann, D; Tognoni, G | 1 |
| Basset, A; Blanc, J; Elghozi, JL | 1 |
| Kozlovskaia, NL; Medvedeva, TIu; Miroshnichenko, NG; Okonova, EB; Plieva, OK; Rudenko, TE; Shonichev, DG; Shvetsov, MIu; Stavrovskaia, EV | 1 |
| Komajda, M | 1 |
| Cohn, JN; Tognoni, G | 1 |
| Carretta, R; Fogari, R; Salvetti, A; Veglio, F; Zoppi, A | 1 |
| Houghton, AR | 1 |
31 review(s) available for valsartan and Chronic Disease
| Article | Year |
|---|---|
Benefits and adverse effects of sacubitril/valsartan in patients with chronic heart failure: A systematic review and meta-analysis.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Hyperkalemia; Hypotension; Mortality; Renal Insufficiency; Risk Assessment; Stroke Volume; Valsartan | 2021 |
Recent advances in the pharmacological therapy of chronic heart failure: Evidence and guidelines.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiac Myosins; Chronic Disease; Glucose; Heart Failure; Humans; Neprilysin; Receptors, Angiotensin; Sodium; Sodium-Glucose Transporter 2; Soluble Guanylyl Cyclase; Stroke Volume; Valsartan; Ventricular Function, Left | 2022 |
Recent advances in the treatment of chronic heart failure.
Topics: Aminobutyrates; Amyloid Neuropathies, Familial; Angiotensin Receptor Antagonists; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hemodynamics; Humans; Iron Deficiencies; Mitral Valve Insufficiency; Monitoring, Physiologic; Sodium-Glucose Transporter 2; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
TaleNeprilysin and Neprilysin inhibition in chronic kidney disease.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzhydryl Compounds; Biphenyl Compounds; Cardiovascular Diseases; Chronic Disease; Disease Models, Animal; Disease Progression; Drug Combinations; Glucosides; Heart Failure; Humans; Mice; Natriuretic Peptides; Neprilysin; Renal Insufficiency, Chronic; Renin-Angiotensin System; Sodium-Glucose Transporter 2 Inhibitors; Valsartan | 2021 |
[New pharmacologic therapies for chronic heart failure].
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Digitalis Glycosides; Drug Combinations; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2017 |
[Acute and chronic heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Cardiac Resynchronization Therapy; Chronic Disease; Defibrillators, Implantable; Diuretics; Drug Combinations; Extracorporeal Membrane Oxygenation; Guideline Adherence; Heart Failure; Heart-Assist Devices; Infusions, Intravenous; Iron; Tetrazoles; Valsartan | 2017 |
Focused Treatment of Heart Failure with Reduced Ejection Fraction Using Sacubitril/Valsartan.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Heart Rate; Humans; Natriuretic Peptides; Neprilysin; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Stroke Volume; Sympathetic Nervous System; Tetrazoles; Valsartan | 2018 |
Cost-Utility Analysis of Sacubitril/Valsartan Use Compared With Standard Care in Chronic Heart Failure Patients With Reduced Ejection Fraction in South Korea.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Health Care Costs; Heart Failure; Humans; Models, Statistical; Republic of Korea; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2019 |
LCZ696 : a new paradigm for the treatment of heart failure?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials, Phase II as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Prospective Studies; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2015 |
[The new drug is much more effective than ACE inhibitors in chronic heart failure].
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Enalapril; Female; Heart Failure, Systolic; Hospitalization; Humans; Male; Middle Aged; Tetrazoles; Valsartan | 2015 |
Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure, Systolic; Humans; Neprilysin; Renin-Angiotensin System; Tetrazoles; Valsartan | 2015 |
Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Enalapril; Heart Failure; Humans; Neprilysin; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Tetrazoles; Valsartan | 2015 |
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Design; Heart Failure; Humans; Neprilysin; Tetrazoles; Valsartan | 2015 |
A Review of New Pharmacologic Treatments for Patients With Chronic Heart Failure With Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Ivabradine; Neprilysin; Prospective Studies; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Sacubitril/Valsartan: A Review in Chronic Heart Failure with Reduced Ejection Fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Heart Failure; Heart Function Tests; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
Heart failure trials on pharmacological therapy in 2015: lessons learned and future outlook.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Medication Therapy Management; Recombinant Proteins; Relaxin; Stroke Volume; Tetrazoles; Valsartan | 2016 |
[Angiotensin-receptor- and neprilysin-inhibition: a new option against heart failure].
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enzyme Inhibitors; Heart Failure; Hospitalization; Humans; Neprilysin; Tetrazoles; Valsartan | 2016 |
Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Heart Failure; Humans; Neprilysin; Quality of Life; Tetrazoles; Valsartan | 2016 |
Pharmacology of heart failure: From basic science to novel therapies.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Drug Combinations; Guanylate Cyclase; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Myosins; Neprilysin; Practice Guidelines as Topic; Renin-Angiotensin System; Tetrazoles; Valsartan | 2016 |
Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; Chronic Disease; Drug Combinations; Endothelin-1; Heart Failure; Humans; Natriuretic Agents; Natriuretic Peptide, Brain; Neprilysin; Receptors, Atrial Natriuretic Factor; Renin-Angiotensin System; Sympathetic Nervous System; Tetrazoles; Valsartan | 2017 |
Evolving therapies for the management of chronic and acute decompensated heart failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials as Topic; Disease Management; Drug Combinations; Ferric Compounds; Heart Failure; Humans; Ivabradine; Maltose; Tetrazoles; Valsartan | 2016 |
The safety of sacubitril-valsartan for the treatment of chronic heart failure.
Topics: Aminobutyrates; Angioedema; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Chronic Disease; Drug Combinations; Enalapril; Heart Failure; Humans; Risk Factors; Tetrazoles; Valsartan | 2017 |
[Recent clinical evidences of RAS inhibitors on chronic kidney diseases].
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2010 |
[Recent advance in kidney and hypertension research].
Topics: Albuminuria; Amides; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Agonists; Catheter Ablation; Cerebrovascular Circulation; Chronic Disease; Diabetic Nephropathies; Drug Therapy, Combination; Evidence-Based Medicine; Fumarates; Humans; Hypertension; Imidazoles; Kidney; Kidney Diseases; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2012 |
[Pharmacological treatment of heart failure].
Topics: Acute Disease; Adrenergic beta-Antagonists; Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiotonic Agents; Chronic Disease; Clinical Trials as Topic; Diuretics; Heart Failure; Humans; Infusions, Intravenous; Pyridazines; Tetrazoles; Valine; Valsartan; Vasodilator Agents | 2003 |
Angiotensin type 1 receptor blockers in chronic kidney disease.
Topics: Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Clinical Trials as Topic; Diabetic Nephropathies; Humans; Kidney Diseases; Losartan; Tetrazoles; Valine; Valsartan | 2004 |
[ARB II in chronic heart failure. Coincidences and divergences. Class effect?].
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Losartan; Systole; Tetrazoles; Valine; Valsartan | 2005 |
Rationale for angiotensin II receptor blocker therapy in chronic heart failure.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Heart Failure; Humans; Long-Term Care; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2000 |
[Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Heart Failure; Humans; Losartan; Myocardial Infarction; Severity of Illness Index; Survival Rate; Tetrazoles; Valine; Valsartan | 2007 |
Anti-angiotensin therapy: new perspectives.
Topics: Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Fumarates; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2007 |
Angiotensin II receptor antagonists in chronic heart failure: where do they fit?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiac Output, Low; Chronic Disease; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
23 trial(s) available for valsartan and Chronic Disease
| Article | Year |
|---|---|
The Impact of Sacrubitril/Valsartan on Clinical Treatment and hs-cTnT and NT-ProBNP Serum Levels and the Left Ventricular Function in Patients with Chronic Heart Failure.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Chronic Disease; Drug Combinations; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Treatment Outcome; Troponin T; Valsartan; Ventricular Function, Left | 2020 |
Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Enalapril; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Quality-Adjusted Life Years; Stroke Volume; Switzerland; Tetrazoles; Valsartan | 2017 |
Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Topics: Aged; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Hemodynamics; Humans; Male; Middle Aged; Mitral Valve; Mitral Valve Insufficiency; Neprilysin; Prospective Studies; Protease Inhibitors; Recovery of Function; Republic of Korea; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left | 2019 |
[Study PARADIGM-HF - a paradigm shift in the treatment of chronic heart failure].
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Cardiotonic Agents; Chronic Disease; Czech Republic; Drug Combinations; Female; Humans; Male; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Prospective Studies; Survival Rate; Tetrazoles; Valsartan; Ventricular Dysfunction, Left | 2015 |
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left | 2016 |
Efficacy and safety of sacubitril/valsartan (LCZ696) in Japanese patients with chronic heart failure and reduced ejection fraction: Rationale for and design of the randomized, double-blind PARALLEL-HF study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Asian People; Biphenyl Compounds; Chronic Disease; Double-Blind Method; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Peptide Fragments; Research Design; Single-Blind Method; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2017 |
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Blood Pressure; Chronic Disease; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Enalapril; Female; Heart Failure; Hospitalization; Humans; Hypotension; Male; Neprilysin; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Heart Failure; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2009 |
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Diuretics; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Proteinuria; Ramipril; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2010 |
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Kidney Diseases; Lipids; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Female; Hawaii; Humans; Hypertension; Imidazoles; Imidazolidines; Kidney; Kidney Diseases; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan | 2010 |
[Antihypertensive and nephroprotective effectiveness of AT1-angiotensin II receptor blocker valsartan in average therapeutic and maximal daily dose in patients with arterial hypertension and chronic kidney disease].
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Chronic Disease; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Receptor, Angiotensin, Type 1; Severity of Illness Index; Tetrazoles; Treatment Outcome; Valine; Valsartan; Vascular Resistance | 2011 |
Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Chronic Disease; Combined Modality Therapy; Cross-Over Studies; Diet, Sodium-Restricted; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Kidney Diseases; Lisinopril; Male; Middle Aged; Patient Compliance; Proteinuria; Sodium Chloride, Dietary; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2011 |
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Survival Rate; Tetrazoles; Time; Valine; Valsartan | 2002 |
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Chronic Disease; Cross-Over Studies; Dextrans; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2003 |
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Topics: Aldosterone; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Tetrazoles; Valine; Valsartan | 2003 |
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cardiovascular Diseases; Chronic Disease; Creatinine; Double-Blind Method; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Humans; Kidney Diseases; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Risk Factors; Survival Rate; Tetrazoles; Valine; Valsartan | 2004 |
Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT.
Topics: Aged; Anemia; Angiotensin II Type 1 Receptor Blockers; Chronic Disease; Female; Heart Failure; Hemoglobins; Humans; Logistic Models; Male; Middle Aged; Morbidity; Multivariate Analysis; Prevalence; Prognosis; Survival Analysis; Tetrazoles; Valine; Valsartan | 2005 |
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan | 2005 |
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling | 2006 |
[Experience in the use of valsartan with the aim to inhibit progression of kidney failure in patients with chronic glomerulonephritis].
Topics: Adult; Antihypertensive Agents; Chronic Disease; Female; Follow-Up Studies; Glomerulonephritis; Humans; Hypertension; Kidney Failure, Chronic; Kidney Function Tests; Male; Middle Aged; Proteinuria; Tetrazoles; Time Factors; Valine; Valsartan | 2001 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Probability; Quality of Life; Stroke Volume; Survival Analysis; Tetrazoles; Valine; Valsartan | 2001 |
Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Chronic Disease; Drug Interactions; Female; Humans; Hypertension; Indomethacin; Lisinopril; Male; Middle Aged; Osteoarthritis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
41 other study(ies) available for valsartan and Chronic Disease
| Article | Year |
|---|---|
Impact of sacubitril/valsartan on implantable defibrillator eligibility in heart failure: a real-world experience.
Topics: Aged; Aminobutyrates; Biosimilar Pharmaceuticals; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Drug Combinations; Female; Heart Failure; Humans; Male; Middle Aged; Patient Selection; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Function, Left; Ventricular Remodeling | 2021 |
Highly suspected valsartan-induced chronic erythema nodosum migrans in a patient with hypertension: a case report.
Topics: Aged; Chronic Disease; Erythema Nodosum; Female; Humans; Hypertension; Valsartan | 2022 |
[Management of chronic heart failure: state of the art according to the 2021 guideline].
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Valsartan | 2022 |
Efficacy of sacubitril valsartan sodium tablet for the treatment of chronic heart failure: A systematic review protocol of randomized controlled trials.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Research Design; Systematic Reviews as Topic; Tablets; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Pharmacodynamic and pharmacokinetic effects of S086, a novel angiotensin receptor neprilysin inhibitor.
Topics: Administration, Oral; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Chronic Disease; Disease Models, Animal; Dogs; Drug Combinations; Heart Failure; Myocardial Ischemia; Neprilysin; Protease Inhibitors; Rats, Sprague-Dawley; Recovery of Function; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left | 2020 |
A systematic approach for introduction of novel treatments to a chronic patient group: sacubitril-valsartan as a case study.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Drug Substitution; Female; Heart Failure; Humans; Male; Medication Therapy Management; Models, Theoretical; Valsartan | 2021 |
[Impact of the COVID-19 pandemic on the management of heart failure outpatient clinics. Lessons during the lockdown restrictions].
Topics: Adrenergic beta-Antagonists; Aged; Ambulatory Care Facilities; Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Biphenyl Compounds; Chronic Disease; Continuity of Patient Care; Coronavirus Infections; COVID-19; Delivery of Health Care; Disease Progression; Drug Combinations; Female; Heart Failure; Humans; Italy; Male; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Pandemics; Pneumonia, Viral; Quarantine; Recurrence; SARS-CoV-2; Sodium Potassium Chloride Symporter Inhibitors; Stroke Volume; Telephone; Tetrazoles; Valsartan; Withholding Treatment | 2020 |
Implantable Cardioverter-Defibrillator Eligibility After Initiation of Sacubitril/Valsartan in Chronic Heart Failure: Insights From PROVE-HF.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Defibrillators, Implantable; Female; Heart Failure; Humans; Male; Valsartan | 2021 |
The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
Topics: Aged; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Clinical Studies as Topic; Drug Combinations; Female; Heart Failure; Humans; Hypertension; Male; Patient Readmission; Prognosis; Severity of Illness Index; Stroke Volume; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left | 2020 |
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2022 |
Topical Reformulation of Valsartan for Treatment of Chronic Diabetic Wounds.
Topics: Administration, Cutaneous; Alloxan; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Chronic Disease; Diabetes Mellitus, Experimental; Female; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptor, Angiotensin, Type 1; Skin; Swine; Swine, Miniature; Time Factors; Treatment Outcome; Valsartan; Wound Healing; Wounds and Injuries | 2018 |
Cost Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeco
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Chronic Disease; Cost-Benefit Analysis; Drug Combinations; Economics, Pharmaceutical; Enalapril; Female; Guidelines as Topic; Heart Failure; Humans; Male; Middle Aged; Models, Economic; Neprilysin; Netherlands; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stroke Volume; Tetrazoles; Valsartan | 2017 |
Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
Topics: Aminobutyrates; Biphenyl Compounds; Cardiovascular Agents; Chronic Disease; Clinical Trials, Phase III as Topic; Colombia; Cost-Benefit Analysis; Denmark; Drug Combinations; Drug Costs; Heart Failure; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Recovery of Function; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; United Kingdom; Valsartan; Ventricular Function, Left | 2018 |
Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Atrial Natriuretic Factor; Biphenyl Compounds; CD146 Antigen; Chronic Disease; Dose-Response Relationship, Drug; Drug Combinations; Echocardiography; Female; Fructosamine; Glucagon-Like Peptide 1; Heart Failure; Humans; Interleukin-1 Receptor-Like 1 Protein; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Substance P; Tetrazoles; Treatment Outcome; Troponin I; Valsartan | 2019 |
Sacubitril/Valsartan in Adult Congenital Heart Disease Patients With Chronic Heart Failure - A Single Centre Case Series and Call for an International Registry.
Topics: Adult; Aminobutyrates; Biphenyl Compounds; Chronic Disease; Drug Combinations; Female; Heart Defects, Congenital; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Registries; Tetrazoles; Valsartan | 2020 |
Sacubitril + valsartan (Entresto°) in chronic heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Patient Selection; Tetrazoles; Treatment Outcome; Valsartan | 2017 |
Real-Life Indications to Sacubitril/Valsartan Treatment in Patients With Chronic Systolic Heart Failure.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Biphenyl Compounds; Chronic Disease; Clinical Decision-Making; Drug Combinations; Eligibility Determination; Female; Guideline Adherence; Heart Failure, Systolic; Humans; Male; Middle Aged; Neprilysin; Practice Guidelines as Topic; Protease Inhibitors; Recovery of Function; Retrospective Studies; Stroke Volume; Tetrazoles; Time Factors; Treatment Outcome; Valsartan; Ventricular Function, Left | 2019 |
Effect of low-dose sacubitril/valsartan on body composition, bioelectrical impedance analysis, heart rate variability and T-peak to T-end index in elderly patients with severe chronic heart failure: a pilot experience.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Body Composition; Chronic Disease; Drug Combinations; Electric Impedance; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Pilot Projects; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Echocardiography; Female; Heart Failure; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Valsartan | 2019 |
Sacubitril/valsartan treatment improved the clinical outcome and reduced the hospitalization rate in three patients with chronic heart failure: a case series.
Topics: Aged; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2019 |
Combination product approved for chronic heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Approval; Drug Combinations; Drug Therapy, Combination; Heart Failure; Humans; Tetrazoles; Valsartan | 2015 |
Will sacubitril-valsartan diminish the clinical utility of B-type natriuretic peptide testing in acute cardiac care?
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Male; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Peptide Fragments; Predictive Value of Tests; Stroke Volume; Tetrazoles; Valsartan | 2017 |
[A new medication - when should one switch?].
Topics: Aged; Aged, 80 and over; Aminobutyrates; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Substitution; Heart Failure; Humans; Tetrazoles; Valsartan | 2016 |
Chronic congestive heart failure - a new therapeutic choice.
Topics: Aminobutyrates; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Canada; Chronic Disease; Drug Combinations; Heart Failure; Humans; Randomized Controlled Trials as Topic; Tetrazoles; Valsartan | 2016 |
Comments on the 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure.
Topics: Acute Disease; Adrenergic beta-Antagonists; Algorithms; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Biphenyl Compounds; Cardiac Resynchronization Therapy; Cardiovascular Agents; Chronic Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Drug Combinations; Early Medical Intervention; Echocardiography; Europe; Extracorporeal Membrane Oxygenation; Heart Failure; Humans; Ivabradine; Mineralocorticoid Receptor Antagonists; Natriuretic Peptides; Practice Guidelines as Topic; Spain; Stroke Volume; Tetrazoles; Valsartan | 2016 |
Sacubitril/Valsartan (Entresto) for Heart Failure.
Topics: Aminobutyrates; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Biphenyl Compounds; Chronic Disease; Drug Combinations; Heart Failure; Humans; Hyperkalemia; Hypotension; Neprilysin; Renal Insufficiency; Severity of Illness Index; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan | 2016 |
The cost effectiveness and cost utility of valsartan in chronic heart failure therapy in Italy: a probabilistic markov model.
Topics: Age Factors; Aged; Antihypertensive Agents; Chronic Disease; Computer Simulation; Cost-Benefit Analysis; Drug Costs; Female; Heart Failure; Hospital Costs; Humans; Italy; Male; Markov Chains; Middle Aged; Models, Statistical; Quality of Life; Quality-Adjusted Life Years; Sex Factors; Tetrazoles; Valine; Valsartan | 2009 |
[CCB uptitration is superior to ARB uptitration in CKD patients who do not reach target blood pressure with ARB/CCB combined therapy].
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Calcium Channel Blockers; Chronic Disease; Drug Therapy, Combination; Glomerular Filtration Rate; Hypertension; Kidney Diseases; Nifedipine; Tetrazoles; Time Factors; Valine; Valsartan | 2010 |
Estimation of financial burden due to oversupply of medications for chronic diseases.
Topics: Aged; Atorvastatin; Chronic Disease; Clopidogrel; Drug Costs; Female; Heptanoic Acids; Hospitals, University; Humans; Male; Middle Aged; Pharmaceutical Preparations; Phenylcarbamates; Pyrroles; Retrospective Studies; Rivastigmine; Rosiglitazone; Tetrazoles; Thailand; Thiazolidinediones; Ticlopidine; Valine; Valsartan | 2012 |
Renoprotective efficacy of valsartan in chronic non-diabetic proteinuric nephropathies with renin-angiotensin system gene polymorphisms.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Chronic Disease; Female; Genotype; Humans; Kidney; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Prospective Studies; Protective Agents; Proteinuria; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2011 |
Comparative effectiveness of individual angiotensin receptor blockers on risk of mortality in patients with chronic heart failure.
Topics: Aged; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Confounding Factors, Epidemiologic; Electronic Health Records; Female; Heart Failure; Hospitalization; Humans; Irbesartan; Losartan; Male; Models, Structural; Proportional Hazards Models; Retrospective Studies; Risk; Tetrazoles; Treatment Outcome; United States; Valine; Valsartan | 2012 |
Cardiovascular protection with danshensu in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Arrhythmias, Cardiac; Blood Pressure; Body Weight; Cardiotonic Agents; Cardiovascular System; Chronic Disease; Drug Administration Schedule; Drug Evaluation, Preclinical; Heart; Heart Function Tests; Hypertension; Lactates; Large-Conductance Calcium-Activated Potassium Channels; Male; Mesenteric Arteries; Molecular Targeted Therapy; Muscle, Smooth, Vascular; Nitric Oxide Synthase Type II; Patch-Clamp Techniques; Phytotherapy; Plant Preparations; Plant Roots; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Salvia miltiorrhiza; Tetrazoles; Valine; Valsartan | 2011 |
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France; Humans; Middle Aged; Pioglitazone; Prescription Drugs; Pyrimidines; Randomized Controlled Trials as Topic; Risedronic Acid; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2012 |
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Evaluation Studies as Topic; Heart Failure; Humans; Incidence; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Stroke Volume; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
Angiotensin receptor blockers and heart failure: still CHARMing after VALIANT?
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Chronic Disease; Heart Failure; Humans; Myocardial Infarction; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2004 |
Statins and symptomatic chronic systolic heart failure: a post-hoc analysis of 5010 patients enrolled in Val-HeFT.
Topics: Aged; Antihypertensive Agents; C-Reactive Protein; Cholesterol; Chronic Disease; Creatinine; Databases, Factual; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Morbidity; Prognosis; Retrospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chronic Disease; Drug Therapy, Combination; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan; Young Adult | 2007 |
Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure.
Topics: Adolescent; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Chronic Disease; Echocardiography, Doppler; Female; Follow-Up Studies; Heart Failure; Humans; Male; Middle Aged; Multicenter Studies as Topic; Quality of Life; Randomized Controlled Trials as Topic; Reference Values; Research Design; Severity of Illness Index; Survival Rate; Tetrazoles; Treatment Outcome; Valine; Valsartan | 1999 |
[Contribution of the renin-angiotensin system to blood pressure variability in hyperthyroid rats].
Topics: Angiotensin I; Angiotensin Receptor Antagonists; Animals; Blood Pressure; Cardiomegaly; Chronic Disease; Disease Models, Animal; Fever; Fourier Analysis; Heart Rate; Hypertension; Hyperthyroidism; Injections, Intraperitoneal; Male; Rats; Rats, Wistar; Renin; Renin-Angiotensin System; Signal Processing, Computer-Assisted; Tachycardia; Tetrazoles; Thyroid Hormones; Thyrotoxicosis; Thyroxine; Valine; Valsartan; Weight Loss | 2000 |
[AT1-blocker in heart failure. Patients are readmitted more infrequently to the clinic].
Topics: Angiotensin Receptor Antagonists; Chronic Disease; Drug Therapy, Combination; Heart Failure; Humans; Patient Readmission; Randomized Controlled Trials as Topic; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2000 |
Are angiotensin II receptor blockers indicated in chronic heart failure?
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Chronic Disease; Heart Failure; Humans; Losartan; Randomized Controlled Trials as Topic; Tetrazoles; Valine; Valsartan | 2002 |